Upstream Bio, Inc. UPB 深 滬
已收盤 02-06 16:00:00 美东时间
26.20
+0.200
+0.77%
華盛通- 最 高27.98
- 今 開26.56
- 成交量 51.79万股
- 最 低 25.94
- 昨 收 26.00
- 總市值 14.16亿
- 52周最高 33.68
- 市盈率 靜 --
- 換手率 0.96%
- 52周最低 5.14
- 委 比 -49.49%
- 總股本 5403.86万
- 歷史最高 33.68
- 量 比 0.78
- 振 幅 7.85%
- 歷史最低 5.14
- 每 手 1
- 風險率 8.08%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
Mizuho Initiates Coverage On Upstream Bio with Outperform Rating, Announces Price Target of $51
Mizuho analyst Joseph Catanzaro initiates coverage on Upstream Bio (NASDAQ:UPB) with a Outperform rating and announces Price Target of $51.
2025-12-18 17:36
美股大行评级 | 最高500美元！MongoDB获18家大行紧急上调目标价；巴克莱下调理想汽车目标价至18美元
今日重点评级关注：B. Riley证券：维持Seabridge Gold"买入"评级，目标价从50美元升至65美元；HC Wainwright & Co.：维持TRX Gold"买入"评级，目标价从1.2美元升至1.4美元
2025-12-03 09:58
LifeSci Capital Initiates Coverage On Upstream Bio with Outperform Rating, Announces Price Target of $43
LifeSci Capital initiates coverage on Upstream Bio (NASDAQ:UPB) with a Outperform rating and announces Price Target of $43.
2025-12-02 20:54
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
2025-11-19 11:01
Evercore ISI Group Initiates Coverage On Upstream Bio with Outperform Rating, Announces Price Target of $40
Evercore ISI Group analyst Cory Kasimov initiates coverage on Upstream Bio (NASDAQ:UPB) with a Outperform rating and announces Price Target of $40.
2025-11-18 20:39
Upstream Bio Q3 EPS $(0.63) Beats $(0.76) Estimate, Sales $683.000K Beat $645.000K Estimate
Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.76) by 17.54 percent. This is a 90.95 percent increase over losses of $(6.96) per share from the
2025-11-05 20:16
美股大行评级 | 麦格理首予哔哩哔哩"跑赢大市"评级，目标价36.03美元； 高盛首予联合健康集团"买入"评级，目标价406美元
今日重点评级关注：摩根士丹利：上调Alvotech评级至"超配"，目标价14美元；蒙特利尔银行：维持PG&E"跑赢大市"评级，目标价从23美元升至25美元
2025-10-15 18:20
Truist Securities Initiates Coverage On Upstream Bio with Buy Rating, Announces Price Target of $47
Truist Securities analyst Danielle Brill initiates coverage on Upstream Bio (NASDAQ:UPB) with a Buy rating and announces Price Target of $47.
2025-10-14 21:09
Upstream Bio Highlights New Respiratory Drug Verekitug With Trial Data
Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented structural and mechanistic data showing
2025-09-30 16:26
